MODELS USED TO ASSESS CARDIOVASCULAR FUNCTION IN GENERAL PHARMACOLOGY

被引：1

作者：

BUNTING, PB ^{[1
]}

SIEGL, PKS ^{[1
]}

机构：

[1] MERCK SHARP & DOHME LTD,RES LABS,DEPT PHARMACOL,W POINT,PA 19486

来源：

DRUG DEVELOPMENT RESEARCH | 1994年 / 32卷 / 04期

关键词：

CARDIOVASCULAR FUNCTION ASSAYS; UNPREDICTED PHARMACOLOGICAL ACTIVITY; PROTOCOL DESIGN;

D O I：

10.1002/ddr.430320410

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In the drug developmental process, information obtained from General Pharmacology assays plays an integral part in determining the future direction of the development. The evaluation of a drug in models of cardiovascular function can provide crucial data on cardiovascular activity unrelated to the drug's principal pharmacological action. These data can guide decision-making steps in safety assessment and clinical studies and address problematic issues from regulatory agencies. While in-depth protocols are necessary at times, in most instances examination of basic cardiovascular parameters (e.g., blood pressure, heart rate, and electrocardiogram) as well as evaluation of cardiovascular responses to selected autonomic nervous system stimulants, will reveal unpredicted pharmacological activities altering cardiovascular function and provide insight into mechanism of action. Through careful design of an appropriate protocol and animal model, detection of undesired cardiovascular activity can be simply and efficiently achieved. (C) 1994 Wiiey-Liss, Inc.

引用

页码：256 / 259

页数：4